The IRA requires health plans serving the Part D market to cover all negotiated drugs, and it has been predicted that CMS ...

While pharmaceutical pricing has been a controversial topic for many years, a new spotlight was shone on it over the past 12 months.

The UK's 14.5% drug rebate reduction may help to quell souring pharma sentiments, which stem from the nation's low spending on innovative drugs.

A friend correctly harangued me about this New York Times piece on Donald Trump’s deal on prescription drugs with the United ...

Moat Index gained 1.53% in November, supported by health care and broader market participation. Merck and Amgen were top Moat ...

Alteogen said it believes there is no impact on the progress of its technology out-licensing from a German court's order to ...

Transformative Growth Ahead for Immunotherapy Drugs as Precision Medicine, AI, and Biologics Propel Market Innovation and ...

The "Companion Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Companion ...

We came across a bullish thesis on Merck & Co., Inc. on Darius Dark Investing’s Substack. In this article, we will summarize ...

Medicare beneficiaries will save as much as 85% off the list price when negotiated prices for 15 blockbuster drugs go into effect in 2027, the Centers for Medicare & Medicaid Services (CMS) said ...

The pharma industry has called the IRA “price setting” and argues that the negotiations have not cut out-of-pocket costs for ...

Merck MRK is going to face a major patent cliff, as its blockbuster PD-L1 therapy Keytruda is nearing loss of exclusivity ...